Skip to main content
. Author manuscript; available in PMC: 2021 Oct 1.
Published in final edited form as: Am J Emerg Med. 2020 Jul 10;38(10):2119–2124. doi: 10.1016/j.ajem.2020.07.016

Table 4.

Multivariable regression results as in Table 3, restricted to only those patients with a urolithiasis diagnosis. Adjusted odds of (1) receiving an opioid analgesic during the ED visit or (2) being discharged from the ED with a prescription opioid analgesic in a population of 1,296 adult ED patients diagnosed with urolithiasis.

Predictor variables (1)
Opioid analgesic
during visit
ORa (95% CI)
(2)
Opioid analgesic
at ED discharge
ORa (95% CI)
Likelihood of urolithiasis diagnosis >50% 1.69 (1.28-2.23) b
Pain severity at arrival to ED (0-10)
 Low (0-3) 1.00 (ref) 1.00 (ref)
 Medium (4-8) 3.74 (2.34-5.96) 1.32 (0.84-2.08)
 High (9 or 10) 7.54 (5.15-11.06) 1.50 (0.95-2.37)
>24 hrs in pain before arrival 0.75 (0.57-1.00) 0.66 (0.49-0.89)
Has health care coverage 1.34 (1.02-1.77) 1.19 (0.79-1.78)
Race\ethnicity
 Non-Hispanic white 1.00 (ref) 1.00 (ref)
 Non-Hispanic Black or African American 0.97 (0.54-1.75) 0.76 (0.47-1.24)
 Hispanic 0.68 (0.48-0.97) 0.88 (0.59-1.32)
 Mixed or other race 0.66 (0.41-1.08) 0.92 (0.59-1.44)
More than high school education 1.06 (0.80-1.39) 1.27 (1.00-1.60)
Self-rated health fair or poor
 Excellent, very good, good 1.00 (ref) 1.00 (ref)
 Fair or poor 1.76 (1.16-2.67) 0.84 (0.60-1.16)
Male gender 0.77 (0.63-0.95) 1.12 (0.84-1.50)
Age 1.01 (1.00-1.02) 1.01 (1.00-1.02)
Months since August 2011 0.98 (0.96-1.01) 0.94 (0.91-0.97)
Online access to state PDMP 1.32 (0.85-2.06) 1.78 (1.10-2.89)
a

Odds ratios estimated by a multivariable model with GEE estimation, a logit link, and robust standard errors clustered within each of 15 hospitals in the study sample of 1,296 adult ED urolithiasis patients with non-missing data for outcomes and variables in model (final sample from Table 1).

b

Variable not included in model.

Abbreviations: ED, emergency department; OR, odds ratio; CI, confidence interval; PDMP, prescription drug monitoring program.